Literature DB >> 4006378

Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism.

H Echizen, B Vogelgesang, M Eichelbaum.   

Abstract

After the oral administration of 160 mg pseudoracemic verapamil (80 mg dideuterodextro (d) isomer and 80 mg levo (l) isomer), the prolongation of the PR interval was assessed in relation to d- and l-verapamil plasma concentrations. Concentration-effect curves were analyzed with the sigmoidal Emax model. Because of stereoselective first-pass metabolism, the mean plasma d- to l-verapamil concentration ratio of 4.5 +/- 1.2 was substantially greater than that of 2.1 +/- 0.3 after intravenous dosing. Compared with the concentration after intravenous injection, the total verapamil concentration after oral dosing consisted of a substantially smaller proportion of the more potent l-isomer. These differences in isomer composition of the total verapamil plasma concentration as a result of the route of administration explain the diminished negative dromotropic potency of racemic verapamil after oral dosing. The concentration required to reach 50% of the maximum effect (EC50) for total verapamil concentration was 129.0 +/- 22.9 ng/ml, which was more than three times higher than that after intravenous injection. To assess the relative contributions of the d- and l-isomers to overall dromotropic potency, changes in the PR interval were measured after separate oral dosing with 250 mg d-verapamil and 100 mg l-verapamil. The EC50 showed an 11-fold difference between the l- (36.9 +/- 14.7 ng/ml) and d- (363.1 +/- 64.2 ng/ml) isomers. The EC50 for the l-isomer concentration after oral pseudoracemic verapamil (20.2 +/- 6.3 ng/ml) did not differ significantly from that after l-verapamil alone (36.9 +/- 14.7 ng/ml). We conclude that the l-isomer determines the negative dromotropic effects of verapamil and that the d-isomer is of minor importance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006378     DOI: 10.1038/clpt.1985.137

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

Authors:  D N John; S Fort; M J Lewis; D K Luscombe
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 3.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 5.  Drug chirality and its clinical significance.

Authors:  A J Hutt; S C Tan
Journal:  Drugs       Date:  1996       Impact factor: 9.546

6.  Bioavailability assessment and pharmacologic response: impact of first-pass loss when both drug and metabolites are active.

Authors:  M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1988-12

7.  Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.

Authors:  Dagmar Busse; Silke Templin; Gerd Mikus; Matthias Schwab; Ute Hofmann; Michel Eichelbaum; Kari T Kivistö
Journal:  Eur J Clin Pharmacol       Date:  2006-07-04       Impact factor: 2.953

Review 8.  Chirality in new drug development. Clinical pharmacokinetic considerations.

Authors:  R L Nation
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

9.  R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.

Authors:  J H Ahmed; J Godden; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.